State-of-the-art of Nuclear Medicine and Molecular Imaging in China: After the First 66 years (1956-2022)

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2022 Jun 6

PMID 35665836

Authors

Xiaoli Lan

Li Huo

Shuren Li

Jing Wang

Weibo Cai

Affiliations

Soon will be listed here.

Citing Articles

Letter to the editor concerning "The status of nuclear medicine in China: the first official national survey".

Dong Y, Zhang S Eur J Nucl Med Mol Imaging. 2024; 51(12):3488-3489.

PMID: 38965143 PMC: 11457675. DOI: 10.1007/s00259-024-06829-0.

Quantitation of dynamic total-body PET imaging: recent developments and future perspectives.

Gu F, Wu Q Eur J Nucl Med Mol Imaging. 2023; 50(12):3538-3557.

PMID: 37460750 PMC: 10547641. DOI: 10.1007/s00259-023-06299-w.

References

Luo H, Yang C, Kuang D, Shi S, Chan A . Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1. Eur J Nucl Med Mol Imaging. 2022; 49(8):2735-2745. DOI: 10.1007/s00259-022-05680-5. View

Qiu D, Li J, Zhang J, Chen M, Gao X, Tang Y . Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2021; 49(8):2821-2832. DOI: 10.1007/s00259-021-05636-1. View

Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C . A prospective randomized, double-blind study to evaluate the diagnostic efficacy of Ga-NODAGA-LM3 and Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2021; 49(5):1613-1622. DOI: 10.1007/s00259-021-05512-y. View

Lu D, Zhou H, Li N, Wang Y, Zhang T, Wang F . Galectin expression detected by Ga-galectracer PET as a predictive biomarker of radiotherapy resistance. Eur J Nucl Med Mol Imaging. 2022; 49(8):2746-2760. DOI: 10.1007/s00259-022-05711-1. View

Huang L, Fang J, Hong S, Liu H, Zhu H, Feng L . MicroPET imaging of bacterial infection with nitroreductase-specific responsive F-labelled nitrogen mustard analogues. Eur J Nucl Med Mol Imaging. 2022; 49(8):2645-2654. DOI: 10.1007/s00259-022-05710-2. View

Xie B, Ding Y, Shui M, Yue L, Gao C, Wyman I . Supramolecular biomaterials for bio-imaging and imaging-guided therapy. Eur J Nucl Med Mol Imaging. 2021; 49(4):1200-1210. DOI: 10.1007/s00259-021-05622-7. View

Badawi R, Shi H, Hu P, Chen S, Xu T, Price P . First Human Imaging Studies with the EXPLORER Total-Body PET Scanner. J Nucl Med. 2019; 60(3):299-303. PMC: 6424228. DOI: 10.2967/jnumed.119.226498. View

Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S . [F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022; 49(8):2761-2773. DOI: 10.1007/s00259-022-05758-0. View

Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H . Comparison of the diagnostic efficacy of Ga-FAPI-04 PET/MR and F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022; 49(8):2877-2888. DOI: 10.1007/s00259-022-05729-5. View

10.

Zhou X, Wang S, Xu X, Meng X, Zhang H, Zhang A . Higher accuracy of [ Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[F]FDG PET/CT in clinical staging of NSCLC. Eur J Nucl Med Mol Imaging. 2022; 49(8):2983-2993. DOI: 10.1007/s00259-022-05818-5. View

11.

Sun T, Wang Z, Wu Y, Gu F, Li X, Bai Y . Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging. Eur J Nucl Med Mol Imaging. 2022; 49(8):2994-3004. PMC: 9106794. DOI: 10.1007/s00259-022-05832-7. View

12.

Gu B, Liu X, Wang S, Xu X, Liu X, Hu S . Head-to-head evaluation of [F]FDG and [ Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging. 2022; 49(8):2889-2901. PMC: 9206606. DOI: 10.1007/s00259-022-05700-4. View

13.

Li M, Younis M, Zhang Y, Cai W, Lan X . Correction to: Clinical summary of fibroblast activation protein inhibitor‑based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022; 49(8):3007. DOI: 10.1007/s00259-022-05823-8. View

14.

Zhao L, Pang Y, Wang Y, Chen J, Zhuang Y, Zhang J . Somatostatin receptor imaging with [Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021; 49(4):1360-1373. DOI: 10.1007/s00259-021-05587-7. View

15.

Song W, Song Y, Li Q, Fan C, Lan X, Jiang D . Advances in aptamer-based nuclear imaging. Eur J Nucl Med Mol Imaging. 2022; 49(8):2544-2559. DOI: 10.1007/s00259-022-05782-0. View

16.

He K, Li P, Zhang Z, Liu J, Liu P, Gong S . Intraoperative near-infrared fluorescence imaging can identify pelvic nerves in patients with cervical cancer in real time during radical hysterectomy. Eur J Nucl Med Mol Imaging. 2022; 49(8):2929-2937. PMC: 9206623. DOI: 10.1007/s00259-022-05686-z. View

17.

Hu J, Li H, Sui Y, Du J . Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging. 2021; 49(8):2514-2530. PMC: 8586637. DOI: 10.1007/s00259-021-05615-6. View

18.

Li H, Ye S, Li L, Zhong J, Yan Q, Zhong Y . F- or Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention. Eur J Nucl Med Mol Imaging. 2022; 49(8):2705-2715. DOI: 10.1007/s00259-022-05757-1. View

19.

Jiang C, Li A, Teng Y, Huang X, Ding C, Chen J . Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022; 49(8):2902-2916. DOI: 10.1007/s00259-022-05717-9. View

20.

Liu G, Yu H, Shi D, Hu P, Hu Y, Tan H . Short-time total-body dynamic PET imaging performance in quantifying the kinetic metrics of F-FDG in healthy volunteers. Eur J Nucl Med Mol Imaging. 2021; 49(8):2493-2503. DOI: 10.1007/s00259-021-05500-2. View